1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsGrant to improve understanding of how to engage adolescents and young adults in vaping cessation treatment is sponsored by National Institute on Drug Abuse (NIDA). This grant aims to improve understanding of how to engage adolescents and young adults in vaping cessation treatment.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
New Study Will Help Youth Quit Vaping – UW-CTRI – UW–Madison U niversity of W isconsin –Madison New Study Will Help Youth Quit Vaping More than 1. 4 million adolescents and 4. 7 million young adults in the United States report vaping, according to FDA and CDC’s National Youth Tobacco Survey.
The majority never smoked. To help them quit, UW-CTRI Researcher and UW Health Pediatric and Internal Medicine Hospitalist Dr. Brian Williams has garnered a new $967,000 5-year K08 grant from the National Institute on Drug Abuse (NIDA). While researchers don’t yet know the full extent of any long-term health effects of vaping, they do have evidence that nicotine alters the adolescent brain.
It increases teens’ and young adults’ risk for: Stunted learning and recall. Diminished enjoyment of activities they normally adore. Yet to date, there have been only two randomized controlled trials on how to help youth quit vaping, one of which studied “This is Quitting,” a popular national texting program designed by TRUTH to help youth ditch vaping.
Researchers found evidence that This is Quitting increased quit rates. “Our goal with this new grant is to improve understanding of how to engage adolescents and young adults in vaping cessation treatment,” Williams said, “and ultimately discover how best to help them to quit. ” He plans to recruit nationwide to examine youth perspectives on strategies to increase engagement with This is Quitting.
Williams plans to evaluate the feasibility, acceptability, and preliminary efficacy of two enhancements to This is Quitting—financial incentives and FDA-approved nicotine-replacement medications. In addition, Williams will use data from the PATH Study to better identify predictors of quit attempts as well as success. UW-CTRI Director Dr. Michael Fiore will serve as Williams’ primary mentor on the project.
“It’s critical that we learn more about how to help youth refrain from all tobacco use,” Fiore said. “In particular, we need more information on how to help teens and young adults to quit vaping. This project will do just that.
I’m enormously proud of Brian for securing this prestigious NIDA K08 grant. ” “I’d like to thank NIDA for their support,” Williams said. “This is an incredible opportunity to learn more about how to help young people quit vaping, expand my research knowledge through targeted curriculum, while also working with an incredible group of mentors and collaborators.
I feel very fortunate. ”
According to the current listing, eligibility includes: Universities and research institutions with expertise in adolescent health, substance abuse, and behavioral interventions are eligible. The specific grant was awarded to a researcher at UW-CTRI. Confirm the full requirements in the official notice before applying.
The current listing shows $967,000 (over five years). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Grant to improve understanding of how to engage adolescents and young adults in vaping cessation treatment is funded by National Institute on Drug Abuse (NIDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read article